Sublingual Versus Intranasal Administration of Dexmedetomidine for Sedation of Children Undergoing Dental Treatment

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (273 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-08-10. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 12.5% (raises risk) · Sponsor's track record
• Design: crossover (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: undergoinganesthesiacontrolledchildrendental
  Phrases that lowered it: healthyadministration ofthe efficacyassess thetreatment
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Phase: 2/3 (raises risk) · Design
• Drug's FAERS reports with a death: 17.3% (lowers risk) · Drug's FDA history
• Minimum age: 5 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 24 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 8 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 92.4% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 2082 (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nebulized Midazolam, Dexmedetomidine, and Their Combination in Sedation of Preschoolers Undergoing Dental Treatment NCT03827408 · started 2017 · scored riskier than 6% of active trials completed
• Intranasal Dexmedetomidine Premedication in Children NCT02250703 · started 2014 · scored riskier than 75% of active trials completed
• Intranasal Versus Nebulized Midazolam in Behaviuor Modification of Preschool Children Undergoing Dental Treatment NCT05883150 · started 2022 · scored riskier than 10% of active trials completed
• A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children NCT05111431 · started 2021 · scored riskier than 6% of active trials completed
• Dexmedetomidine Compared to Ketofol for Sedation in Paediatrics NCT04678050 · started 2020 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.